Hepcidin resistance in dysmetabolic iron overload
Background & Aims Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. Methods We evaluated 18 patients with DIOS,...
Saved in:
Published in | Liver international Vol. 36; no. 10; pp. 1540 - 1548 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background & Aims
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.
Methods
We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24‐h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.
Results
Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the‐curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).
Conclusions
Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration. |
---|---|
AbstractList | Background & Aims
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.
Methods
We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24‐h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.
Results
Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the‐curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).
Conclusions
Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration. Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores. Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016). Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration. Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.BACKGROUND & AIMSDysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.METHODSWe evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).RESULTSDysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.CONCLUSIONSDysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration. |
Author | Francione, Paolo Rametta, Raffaela Iuculano, Federica Borroni, Vittorio Girelli, Domenico Castagna, Annalisa Pelusi, Serena Valenti, Luca Dongiovanni, Paola Fargion, Silvia Fatta, Erika |
Author_xml | – sequence: 1 givenname: Raffaela surname: Rametta fullname: Rametta, Raffaela organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy – sequence: 2 givenname: Paola surname: Dongiovanni fullname: Dongiovanni, Paola organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy – sequence: 3 givenname: Serena surname: Pelusi fullname: Pelusi, Serena organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy – sequence: 4 givenname: Paolo surname: Francione fullname: Francione, Paolo organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy – sequence: 5 givenname: Federica surname: Iuculano fullname: Iuculano, Federica organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy – sequence: 6 givenname: Vittorio surname: Borroni fullname: Borroni, Vittorio organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy – sequence: 7 givenname: Erika surname: Fatta fullname: Fatta, Erika organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy – sequence: 8 givenname: Annalisa surname: Castagna fullname: Castagna, Annalisa organization: Policlinico G.B. Rossi, Department of Medicine, Università di Verona, Verona, Italy – sequence: 9 givenname: Domenico surname: Girelli fullname: Girelli, Domenico organization: Policlinico G.B. Rossi, Department of Medicine, Università di Verona, Verona, Italy – sequence: 10 givenname: Silvia surname: Fargion fullname: Fargion, Silvia organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy – sequence: 11 givenname: Luca surname: Valenti fullname: Valenti, Luca email: luca.valenti@unimi.it, luca.valenti@unimi.it organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26998752$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kMtOwzAQRS1URGlhwQ-gLGGRNmMnTrxEFX2ICiQKZWk5jiMZ3LjYaaF_T6CPBYLZeCydc6W5HdSqbKUQuoCoB830jV73gACOj9ApxGkWEkygddgxaaOO969RBIwlcILamDKWpQk-RTBWS6kLXQVOee1rUUkVNL9i4xeqFrk1Wgba2Sqwa-WMFcUZOi6F8ep893bR8_D2aTAOpw-jyeBmGkpCSRyyqJRZjglNaU5pAUKQOMszIjMopFQkjUgUY5KwVAAVkGeqwEmCS5YyQnNZkC662uYunX1fKV_zhfZSGSMqZVeeQwYMmtsi3KCXO3SVL1TBl04vhNvw_ZkN0N8C0lnvnSq51LWota1qJ7ThEPHvInlTJP8psjGufxn70L_YXfqHNmrzP8ink_neCLdG07j6PBjCvXGakjThL_cjPrujbDgfzfgj-QLD3Y-G |
CitedBy_id | crossref_primary_10_3748_wjg_v29_i4_616 crossref_primary_10_1515_cclm_2023_0540 crossref_primary_10_1016_j_lpm_2017_05_036 crossref_primary_10_1016_j_metabol_2024_155953 crossref_primary_10_3390_jcm10092008 crossref_primary_10_1002_ajh_25679 crossref_primary_10_1111_liv_13513 crossref_primary_10_1016_j_clnu_2019_02_012 crossref_primary_10_3390_physiologia2010001 crossref_primary_10_1097_HCO_0000000000000511 crossref_primary_10_3390_endocrines4010002 crossref_primary_10_1016_j_aohep_2022_100707 crossref_primary_10_1016_j_ejphar_2019_172614 crossref_primary_10_17941_agd_1338597 crossref_primary_10_1194_jlr_P090449 crossref_primary_10_1146_annurev_nutr_071816_064559 crossref_primary_10_3390_ijms21103505 crossref_primary_10_1002_hep4_2012 crossref_primary_10_1111_jgh_15971 crossref_primary_10_1111_liv_14539 crossref_primary_10_1007_s00109_017_1596_3 crossref_primary_10_1111_liv_14333 crossref_primary_10_1210_clinem_dgad749 crossref_primary_10_1186_s12876_018_0804_0 crossref_primary_10_1038_s41574_023_00807_6 crossref_primary_10_32725_jab_2022_016 crossref_primary_10_1186_s10020_018_0008_7 crossref_primary_10_1111_apt_15173 |
Cites_doi | 10.1016/j.numecd.2010.01.003 10.1530/eje.1.02083 10.1016/j.jhep.2009.01.029 10.3324/haematol.2009.010322 10.1111/j.1478-3231.2011.02520.x 10.1002/hep.21886 10.1016/j.jhep.2011.05.008 10.1016/j.jhep.2006.09.018 10.2337/diabetes.51.4.1000 10.1016/j.ajpath.2013.02.019 10.1016/j.jprot.2009.08.003 10.1093/qjmed/hcq170 10.1371/journal.pone.0048804 10.1126/science.1176639 10.1016/S0016-5085(99)70401-4 10.1172/JCI44421 10.3748/wjg.v20.i11.3002 10.1111/j.1572-0241.2007.01192.x 10.1371/journal.pone.0134635 10.1100/tsw.2011.130 10.3748/wjg.14.4745 10.1210/jc.2010-2682 10.1111/j.1478-3231.2004.0988.x 10.1182/blood-2011-02-337907 10.1016/S1590-8658(03)00025-2 10.2337/diacare.28.8.2061 10.1016/j.bcmd.2003.08.003 10.1053/j.gastro.2013.12.016 10.2337/dc05-1592 10.1053/j.gastro.2009.11.013 10.1002/hep.24038 10.2337/dc12-0505 10.3324/haematol.2010.033449 10.1159/000243791 10.1016/j.jhep.2008.09.011 10.1002/hep.27774 10.1016/j.jhep.2010.05.016 10.1053/gast.2002.32403 10.2337/diacare.23.1.57 10.1016/j.jhep.2008.03.011 10.1016/j.jhep.2010.05.023 10.2337/diacare.27.10.2422 10.3945/ajcn.111.015743 10.1371/journal.pone.0116855 |
ContentType | Journal Article |
Copyright | 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1111/liv.13124 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1478-3231 |
EndPage | 1548 |
ExternalDocumentID | 26998752 10_1111_liv_13124 LIV13124 ark_67375_WNG_SK69FVGS_R |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano – fundername: Associazione Malattie Metaboliche del Fegato ONLUS |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
ID | FETCH-LOGICAL-c3634-90fc8b23676b66d1aa348b83c81dcce37030423597a16a1b8ed2552f97936bcd3 |
IEDL.DBID | DR2 |
ISSN | 1478-3223 1478-3231 |
IngestDate | Fri Jul 11 11:55:53 EDT 2025 Wed Feb 19 02:40:33 EST 2025 Tue Jul 01 04:10:01 EDT 2025 Thu Apr 24 22:50:18 EDT 2025 Wed Jan 22 16:27:54 EST 2025 Wed Oct 30 09:51:30 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | iron nonalcoholic fatty liver disease liver hereditary haemochromatosis |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3634-90fc8b23676b66d1aa348b83c81dcce37030423597a16a1b8ed2552f97936bcd3 |
Notes | ark:/67375/WNG-SK69FVGS-R Associazione Malattie Metaboliche del Fegato ONLUS istex:74A026B96B6C4F7189190647D6AA7DE29A70B031 Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano ArticleID:LIV13124 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-8909-0345 |
PMID | 26998752 |
PQID | 1819122302 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1819122302 pubmed_primary_26998752 crossref_citationtrail_10_1111_liv_13124 crossref_primary_10_1111_liv_13124 wiley_primary_10_1111_liv_13124_LIV13124 istex_primary_ark_67375_WNG_SK69FVGS_R |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-10 October 2016 2016-10-00 20161001 |
PublicationDateYYYYMMDD | 2016-10-01 |
PublicationDate_xml | – month: 10 year: 2016 text: 2016-10 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Liver international |
PublicationTitleAlternate | Liver Int |
PublicationYear | 2016 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Trombini P, Paolini V, Pelucchi S, et al. Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 2011; 31: 994-1000. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010; 53: 941-9. Wrede CE, Buettner R, Bollheimer LC, et al. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-40. Dongiovanni P, Lanti C, Gatti S, et al. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS ONE 2015; 10: e0116855. Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172-8. Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084-9. Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology 2015; 62: 751-61. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011; 117: e218-25. Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4. Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-3. Valenti L, Canavesi E, Galmozzi E, et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010b; 53: 927-33. Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011; 96: 958-61. Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study. QJM 2011b; 104: 141-9. Camaschella C, Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. ScientificWorldJournal 2011; 11: 1357-66. Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012; 122: 3529-40. Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745-52. Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57. Ruivard M, Laine F, Ganz T, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219-25. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8. Valenti L, Maloberti A, Signorini S, et al. Iron stores, hepcidin, and aortic stiffness in individuals with hypertension. PLoS ONE 2015; 10: e0134635. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-301. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63. Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014; 146: 1060-9. Valenti L, Rametta R, Dongiovanni P, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 2012; 7: e48804. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011a; 21: 568-75. Zheng X, Jiang T, Wu H, et al. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 2012; 94: 1012-9. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-32. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7. Girelli D, Trombini P, Busti F, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011; 96: 500-6. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-8. Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94: 1748-52. Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013; 182: 2254-63. Valenti L, Fracanzani AL, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-10. Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-80. Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010; 73: 527-36. Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010a; 138: 905-12. Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008; 49: 123-33. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013; 36: 309-15. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63. Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-7. 2007; 102 2010; 53 2012; 122 2011; 117 2004; 27 2000; 23 2010a; 138 2002; 51 2015; 10 2004; 24 2008; 14 2003; 35 2011; 53 2011; 31 2011; 96 2011; 55 2006; 154 2011; 11 2010b; 53 2005; 28 2013; 182 2014; 20 2012; 94 2004; 32 2013; 36 2009; 50 2015; 62 2009; 94 2011b; 104 2002; 122 2008; 49 2011a; 21 2009; 122 2006; 29 1999; 117 2012; 7 2007; 46 2010; 73 2009; 325 2014; 146 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – reference: Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7. – reference: Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010a; 138: 905-12. – reference: Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology 2015; 62: 751-61. – reference: Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57. – reference: Ruivard M, Laine F, Ganz T, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219-25. – reference: Wrede CE, Buettner R, Bollheimer LC, et al. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-40. – reference: Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013; 182: 2254-63. – reference: Valenti L, Maloberti A, Signorini S, et al. Iron stores, hepcidin, and aortic stiffness in individuals with hypertension. PLoS ONE 2015; 10: e0134635. – reference: Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011a; 21: 568-75. – reference: Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8. – reference: Trombini P, Paolini V, Pelucchi S, et al. Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 2011; 31: 994-1000. – reference: Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63. – reference: Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-3. – reference: Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94: 1748-52. – reference: Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084-9. – reference: Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6. – reference: Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010; 73: 527-36. – reference: Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-301. – reference: Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study. QJM 2011b; 104: 141-9. – reference: Zheng X, Jiang T, Wu H, et al. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 2012; 94: 1012-9. – reference: Girelli D, Trombini P, Busti F, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011; 96: 500-6. – reference: Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63. – reference: Valenti L, Canavesi E, Galmozzi E, et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010b; 53: 927-33. – reference: Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172-8. – reference: Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-7. – reference: Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012; 122: 3529-40. – reference: Valenti L, Fracanzani AL, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-10. – reference: Camaschella C, Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. ScientificWorldJournal 2011; 11: 1357-66. – reference: Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4. – reference: Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-8. – reference: Valenti L, Rametta R, Dongiovanni P, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 2012; 7: e48804. – reference: Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014; 146: 1060-9. – reference: Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011; 96: 958-61. – reference: Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011; 117: e218-25. – reference: Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010; 53: 941-9. – reference: Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86. – reference: Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9. – reference: Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-80. – reference: Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745-52. – reference: Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-32. – reference: Dongiovanni P, Lanti C, Gatti S, et al. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS ONE 2015; 10: e0116855. – reference: Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8. – reference: Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008; 49: 123-33. – reference: Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013; 36: 309-15. – volume: 117 start-page: e218 year: 2011 end-page: 25 article-title: Serum hepcidin: reference ranges and biochemical correlates in the general population publication-title: Blood – volume: 11 start-page: 1357 year: 2011 end-page: 66 article-title: Molecular mechanisms regulating hepcidin revealed by hepcidin disorders publication-title: ScientificWorldJournal – volume: 46 start-page: 700 year: 2007 end-page: 7 article-title: NAFLD and hyperinsulinemia are major determinants of serum ferritin levels publication-title: J Hepatol – volume: 73 start-page: 527 year: 2010 end-page: 36 article-title: Hepcidin assay in serum by SELDI‐TOF‐MS and other approaches publication-title: J Proteomics – volume: 325 start-page: 877 year: 2009 end-page: 80 article-title: ER stress controls iron metabolism through induction of hepcidin publication-title: Science – volume: 32 start-page: 131 year: 2004 end-page: 8 article-title: The ferroportin disease publication-title: Blood Cells Mol Dis – volume: 117 start-page: 1155 year: 1999 end-page: 63 article-title: Insulin resistance‐associated hepatic iron overload publication-title: Gastroenterology – volume: 50 start-page: 351 year: 2009 end-page: 7 article-title: Liver iron excess in patients with hepatocellular carcinoma developed on non‐alcoholic steato‐hepatitis publication-title: J Hepatol – volume: 23 start-page: 57 year: 2000 end-page: 63 article-title: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity publication-title: Diabetes Care – volume: 14 start-page: 4745 year: 2008 end-page: 52 article-title: Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome publication-title: World J Gastroenterol – volume: 27 start-page: 2422 year: 2004 end-page: 8 article-title: Serum ferritin and risk of the metabolic syndrome in U.S. adults publication-title: Diabetes Care – volume: 20 start-page: 3002 year: 2014 end-page: 10 article-title: A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia publication-title: World J Gastroenterol – volume: 122 start-page: 78 year: 2009 end-page: 86 article-title: The role of hepcidin in iron metabolism publication-title: Acta Haematol – volume: 104 start-page: 141 year: 2011b end-page: 9 article-title: Venesection for non‐alcoholic fatty liver disease unresponsive to lifestyle counselling – a propensity score‐adjusted observational study publication-title: QJM – volume: 10 start-page: e0116855 year: 2015 article-title: High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload publication-title: PLoS ONE – volume: 29 start-page: 2084 year: 2006 end-page: 9 article-title: Relationships of serum ferritin, transferrin saturation, and HFE mutations and self‐reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study publication-title: Diabetes Care – volume: 46 start-page: 1291 year: 2007 end-page: 301 article-title: Hemochromatosis: an endocrine liver disease publication-title: Hepatology – volume: 182 start-page: 2254 year: 2013 end-page: 63 article-title: Dietary iron overload induces visceral adipose tissue insulin resistance publication-title: Am J Pathol – volume: 50 start-page: 1219 year: 2009 end-page: 25 article-title: Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin publication-title: J Hepatol – volume: 35 start-page: 172 year: 2003 end-page: 8 article-title: Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis publication-title: Dig Liver Dis – volume: 28 start-page: 2061 year: 2005 end-page: 3 article-title: Prevalence of body iron excess in the metabolic syndrome publication-title: Diabetes Care – volume: 94 start-page: 1748 year: 2009 end-page: 52 article-title: Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization publication-title: Haematologica – volume: 21 start-page: 568 year: 2011a end-page: 75 article-title: Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease publication-title: Nutr Metab Cardiovasc Dis – volume: 31 start-page: 994 year: 2011 end-page: 1000 article-title: Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome publication-title: Liver Int – volume: 55 start-page: 920 year: 2011 end-page: 32 article-title: Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target publication-title: J Hepatol – volume: 102 start-page: 1251 year: 2007 end-page: 8 article-title: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case‐control study publication-title: Am J Gastroenterol – volume: 10 start-page: e0134635 year: 2015 article-title: Iron stores, hepcidin, and aortic stiffness in individuals with hypertension publication-title: PLoS ONE – volume: 94 start-page: 1012 year: 2012 end-page: 9 article-title: Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis publication-title: Am J Clin Nutr – volume: 96 start-page: 958 year: 2011 end-page: 61 article-title: Insulin sensitivity and liver fat: role of iron load publication-title: J Clin Endocrinol Metab – volume: 62 start-page: 751 year: 2015 end-page: 61 article-title: Increased duodenal iron absorption through up‐regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis publication-title: Hepatology – volume: 53 start-page: 448 year: 2011 end-page: 57 article-title: Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease publication-title: Hepatology – volume: 122 start-page: 3529 year: 2012 end-page: 40 article-title: Adipocyte iron regulates adiponectin and insulin sensitivity publication-title: J Clin Invest – volume: 49 start-page: 123 year: 2008 end-page: 33 article-title: Hepcidin and iron‐related gene expression in subjects with Dysmetabolic Hepatic Iron Overload publication-title: J Hepatol – volume: 53 start-page: 927 year: 2010b end-page: 33 article-title: Beta‐globin mutations are associated with parenchymal siderosis and fibrosis in patients with non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 138 start-page: 905 year: 2010a end-page: 12 article-title: HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 122 start-page: 931 year: 2002 end-page: 9 article-title: Effect of iron depletion in carbohydrate‐intolerant patients with clinical evidence of nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 154 start-page: 333 year: 2006 end-page: 40 article-title: Association between serum ferritin and the insulin resistance syndrome in a representative population publication-title: Eur J Endocrinol – volume: 96 start-page: 500 year: 2011 end-page: 6 article-title: A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis publication-title: Haematologica – volume: 146 start-page: 1060 year: 2014 end-page: 9 article-title: Gluconeogenic signals regulate iron homeostasis via hepcidin in mice publication-title: Gastroenterology – volume: 51 start-page: 1000 year: 2002 end-page: 4 article-title: Blood letting in high‐ferritin type 2 diabetes: effects on insulin sensitivity and beta‐cell function publication-title: Diabetes – volume: 36 start-page: 309 year: 2013 end-page: 15 article-title: Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study publication-title: Diabetes Care – volume: 7 start-page: e48804 year: 2012 article-title: The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease publication-title: PLoS ONE – volume: 53 start-page: 941 year: 2010 end-page: 9 article-title: Ferroportin disease: a systematic meta‐analysis of clinical and molecular findings publication-title: J Hepatol – volume: 24 start-page: 471 year: 2004 end-page: 6 article-title: Effects of venesections and restricted diet in patients with the insulin‐resistance hepatic iron overload syndrome publication-title: Liver Int – ident: e_1_2_8_12_1 doi: 10.1016/j.numecd.2010.01.003 – ident: e_1_2_8_4_1 doi: 10.1530/eje.1.02083 – ident: e_1_2_8_44_1 doi: 10.1016/j.jhep.2009.01.029 – ident: e_1_2_8_45_1 doi: 10.3324/haematol.2009.010322 – ident: e_1_2_8_32_1 doi: 10.1111/j.1478-3231.2011.02520.x – ident: e_1_2_8_33_1 doi: 10.1002/hep.21886 – ident: e_1_2_8_3_1 doi: 10.1016/j.jhep.2011.05.008 – ident: e_1_2_8_5_1 doi: 10.1016/j.jhep.2006.09.018 – ident: e_1_2_8_24_1 doi: 10.2337/diabetes.51.4.1000 – ident: e_1_2_8_25_1 doi: 10.1016/j.ajpath.2013.02.019 – ident: e_1_2_8_38_1 doi: 10.1016/j.jprot.2009.08.003 – ident: e_1_2_8_21_1 doi: 10.1093/qjmed/hcq170 – ident: e_1_2_8_28_1 doi: 10.1371/journal.pone.0048804 – ident: e_1_2_8_39_1 doi: 10.1126/science.1176639 – ident: e_1_2_8_6_1 doi: 10.1016/S0016-5085(99)70401-4 – ident: e_1_2_8_26_1 doi: 10.1172/JCI44421 – ident: e_1_2_8_22_1 doi: 10.3748/wjg.v20.i11.3002 – ident: e_1_2_8_10_1 doi: 10.1111/j.1572-0241.2007.01192.x – ident: e_1_2_8_18_1 doi: 10.1371/journal.pone.0134635 – ident: e_1_2_8_31_1 doi: 10.1100/tsw.2011.130 – ident: e_1_2_8_2_1 doi: 10.3748/wjg.14.4745 – ident: e_1_2_8_11_1 doi: 10.1210/jc.2010-2682 – ident: e_1_2_8_23_1 doi: 10.1111/j.1478-3231.2004.0988.x – ident: e_1_2_8_36_1 doi: 10.1182/blood-2011-02-337907 – ident: e_1_2_8_7_1 doi: 10.1016/S1590-8658(03)00025-2 – ident: e_1_2_8_9_1 doi: 10.2337/diacare.28.8.2061 – ident: e_1_2_8_41_1 doi: 10.1016/j.bcmd.2003.08.003 – ident: e_1_2_8_40_1 doi: 10.1053/j.gastro.2013.12.016 – ident: e_1_2_8_14_1 doi: 10.2337/dc05-1592 – ident: e_1_2_8_15_1 doi: 10.1053/j.gastro.2009.11.013 – ident: e_1_2_8_16_1 doi: 10.1002/hep.24038 – ident: e_1_2_8_19_1 doi: 10.2337/dc12-0505 – ident: e_1_2_8_35_1 doi: 10.3324/haematol.2010.033449 – ident: e_1_2_8_27_1 doi: 10.1159/000243791 – ident: e_1_2_8_17_1 doi: 10.1016/j.jhep.2008.09.011 – ident: e_1_2_8_43_1 doi: 10.1002/hep.27774 – ident: e_1_2_8_42_1 doi: 10.1016/j.jhep.2010.05.016 – ident: e_1_2_8_20_1 doi: 10.1053/gast.2002.32403 – ident: e_1_2_8_37_1 doi: 10.2337/diacare.23.1.57 – ident: e_1_2_8_34_1 doi: 10.1016/j.jhep.2008.03.011 – ident: e_1_2_8_29_1 doi: 10.1016/j.jhep.2010.05.023 – ident: e_1_2_8_8_1 doi: 10.2337/diacare.27.10.2422 – ident: e_1_2_8_13_1 doi: 10.3945/ajcn.111.015743 – ident: e_1_2_8_30_1 doi: 10.1371/journal.pone.0116855 |
SSID | ssj0019951 |
Score | 2.340654 |
Snippet | Background & Aims
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose... Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1540 |
SubjectTerms | Adult Aged Case-Control Studies Female Ferritins - blood Hemochromatosis - complications Hemoglobins - metabolism Hepcidins - blood Hepcidins - metabolism hereditary haemochromatosis Humans iron Iron - metabolism Iron Overload - metabolism Iron Overload - physiopathology Italy Linear Models liver Liver - pathology Male Middle Aged Non-alcoholic Fatty Liver Disease - complications nonalcoholic fatty liver disease Young Adult |
Title | Hepcidin resistance in dysmetabolic iron overload |
URI | https://api.istex.fr/ark:/67375/WNG-SK69FVGS-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.13124 https://www.ncbi.nlm.nih.gov/pubmed/26998752 https://www.proquest.com/docview/1819122302 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CAqWXNk362L5wSwm5eFnZsmzRUyjdbB_JIWnSHApCGsuwZOMN2d3S9Nd3Rn7QlBRKb36MjayZ0XwjjT4DvEmwcnLkMJbWVjFFiCIuhNexKCuNFK_zLJA9HxyqyYn8eJadrcHbbi9Mww_RT7ixZ4Txmh3cusVvTj6bfh-KlMITjb9cq8WA6KinjuKdxyHZkrz8TzGwZRXiKp7-yRuxaIO79cdtQPMmbg2BZ3wfvnVNbupNzoerpRvizz_YHP_zmzbhXgtIo73Ggh7Amq-3YHuvpmT84jraiUKJaJh734I7B-1K_DaIib_EKQW-iPJ1xqBkPBGdldeLC78ky5pNMeItdBHXiM7mtnwIJ-P3X95N4vb3CzGmKpWxHlVYOGZ4U06pUlibysIVKRLERfQpjxUExigjsUJZ4QpfUn6SVJpcXjks00ewXs9r_wQi1OgsWplh4WXulfZWqoSu6DTLhS4HsNspwmDLTc6_yJiZLkehnjGhZwbwuhe9bAg5bhPaCdrsJezVOVew5Zn5erhvjj8pPT7dPzZHA3jVqduQX_Fiia39fLUwgjNZsptRMoDHjR30b0sUJal5Rnd2gzb_3hDz-cNpOHj676LP4C6hMtVUDD6H9eXVyr8g5LN0L4OJ_wIXbPyD |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTQJeGGx8lDEICE17SVUnjhNLvEyMrrC1D_uiL8iyHUeq1qXT1qJtfz13zocYGhLiLU4ukWPf-X5nn38G-BjZwvCesSHXugjRQ2RhxpwMWV5Ii_46TTzZ83AkBif82zgZL8GnZi9MxQ_RTriRZfjxmgycJqR_s_Lp5GeXxeifHsAKnehNzPm7hy15FO099uEWpwQA9II1rxDl8bSv3vFGK9Sw1_dBzbvI1bue_ir8aCpdZZycdRdz07W3f_A5_u9fPYUnNSYNdiolegZLrlyD9Z0S4_Hzm2Ar8Fmifvp9DR4O68X4dWADd2En6PsCDNkJhqL-BFjKb67O3RyVazqxAe2iCyhNdDrT-XM46X85_jwI6xMYQhuLmIeyV9jMEMmbMELkTOuYZyaLLaJca11MwwXiMQxKNBOamczlGKJEhUSrF8bm8QtYLmelewWBldZoq3liM8dTJ6TTXER4R8ZJymTege2mJ5St6cnplIypasIUbBnlW6YDH1rRi4qT4z6hLd-drYS-PKMktjRR30d76mhfyP7p3pE67MD7pr8Vmhatl-jSzRZXilEwi4rTizrwslKE9muRwDg1TfDJtu_Ov1dEHXw99Rev_130HTwaHA8PsDza34DHCNJElUD4Bpbnlwu3iUBobt56ff8F4EQArg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8xkNBe9gH76Ma2DE2Il1R14jixeEJjpcCoEAzGwyTLvjhSRUkraKexv35n50NjYhLiLU4ukWPf-X5nn38G-BRhYXjPYMi1LkLyEFmYMStDlhcSyV-niSd7PhyKwSnfP0_OF2Cr2QtT8UO0E27OMvx47Qx8mhd_Gfl49LPLYnJPj2CJi5505zbsHLfcUW7rsY-2uFv_JydY0wq5NJ721VvOaMm166-7kOZt4Oo9T_8p_GjqXCWcXHTnM9PF3__QOT7wp57BkxqRBtuVCj2HBVuuwOp2SdH45U2wEfgcUT_5vgLLh_VS_CqwgZ3iiDxfQAG7A6GkPQGV8pvrSzsj1RqPMHB76AKXJDqe6PwFnPa_fPs8COvzF0KMRcxD2SswM47iTRghcqZ1zDOTxUgYF9HGbrAgNEYhiWZCM5PZnAKUqJBk88JgHr-ExXJS2tcQoESjUfMEM8tTK6TVXER0R8ZJymTegc2mIxTW5OTujIyxaoIUahnlW6YD663otGLkuEtow_dmK6GvLlwKW5qo78NddXIgZP9s90Qdd-Bj092KDMutlujSTubXirlQlvSmF3XgVaUH7dciQVFqmtCTTd-b_6-I-rp35i_e3F_0Aywf7fSpODx4C48JoYkqe3ANFmdXc_uOUNDMvPfa_gfebf9O |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepcidin+resistance+in+dysmetabolic+iron+overload&rft.jtitle=Liver+international&rft.au=Rametta%2C+Raffaela&rft.au=Dongiovanni%2C+Paola&rft.au=Pelusi%2C+Serena&rft.au=Francione%2C+Paolo&rft.date=2016-10-01&rft.issn=1478-3231&rft.eissn=1478-3231&rft.volume=36&rft.issue=10&rft.spage=1540&rft_id=info:doi/10.1111%2Fliv.13124&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |